Immunic Inc [IMUX] stock prices are down -0.27% to $0.77 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The IMUX shares have gain 13.65% over the last week, with a monthly amount drifted -27.77%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, H.C. Wainwright started tracking the stock with Buy rating on November 25, 2024, and set its price target to $10. B. Riley Securities started tracking the stock assigning a Buy rating and suggested a price target of $6 on August 27, 2024. SVB Leerink downgraded its rating to a Mkt Perform but $5 remained the price target by the analyst firm on October 21, 2022. In a note dated April 15, 2021, Aegis Capital initiated an Buy rating and provided a target price of $55 on this stock.
The stock price of Immunic Inc [IMUX] has been fluctuating between $0.56 and $2.11 over the past year. Currently, Wall Street analysts expect the stock to reach $5 within the next 12 months. Immunic Inc [NASDAQ: IMUX] shares were valued at $0.77 at the most recent close of the market. An investor can expect a potential return of 549.35% based on the average IMUX price forecast.
Analyzing the IMUX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -4.7, Equity is -3.27 and Total Capital is 19.89. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.7074 points at the first support level, and at 0.6420 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.8559, and for the 2nd resistance point, it is at 0.9390.
Ratios To Look Out For
It’s worth pointing out that Immunic Inc [NASDAQ:IMUX]’s Current Ratio is 0.74. On the other hand, the Quick Ratio is 0.74, and the Cash Ratio is 0.56.
Transactions by insiders
Recent insider trading involved Neermann Joerg, Director, that happened on Jun 04 ’25 when 70000.0 shares were purchased. Director, Neermann Joerg completed a deal on Jun 05 ’25 to buy 30000.0 shares. Meanwhile, Chief Financial Officer Whaley Glenn bought 45000.0 shares on Jun 03 ’25.
